BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Zullo A, Hassan C, Ridola L, Lorenzetti R, Campo SM, Riggio O. Rifaximin therapy and hepatic encephalopathy: Pros and cons. World J Gastrointest Pharmacol Ther 2012; 3(4): 62-67 [PMID: 22966484 DOI: 10.4292/wjgpt.v3.i4.62]
URL: https://www.wjgnet.com/1007-9327/full/v3/i4/62.htm
Number Citing Articles
1
E. M. Ledeneva, A. L. Vertkin, Yu. V. Sediakina, N. A. Burakova, M. M. Shamuilova, S. S. Kurdjieva. Management of patients with liver cirrhosis at outpatient stage: How not to miss it?Medical alphabet 2023; (35): 14 doi: 10.33667/2078-5631-2022-35-14-18
2
Abhishek Basappanamalige Lokesh Reddy, Sabeena Kizhedath, Bindhu Vasudevan. COMPARISON OF RIFAXIMIN, LACTULOSE WITH RIFAXIMIN, LACTULOSE, BRANCHED CHAIN AMINOACIDS (BCAA) IN GRADE 1 TO GRADE 3 OF HEPATIC ENCEPHALOPATHY- NON RANDOMIZED CONTROLLED TRIAL STUDYJournal of Evolution of Medical and Dental Sciences 2017; 6(74): 5314 doi: 10.14260/Jemds/2017/1153
3
Marcos F. Ocaña-Sánchez, Gabriel A. Soto-Ojeda, Yolanda Cocotle-Ronzón, Cesar Soria-Fregozo, Alberto Sánchez-Medina, Rosa V. García-Rodríguez, Juan F. Rodríguez-Landa, Erick J. Corro-Méndez, Minerva Hernández-Lozano. Flaxseed Oil (Linum usitatissimum) Prevents Cognitive and Motor Damage in Rats with HyperammonemiaNutrients 2023; 15(21): 4550 doi: 10.3390/nu15214550
4
Leen Z. Hasan, George Y. Wu. Novel Agents in the Management of Hepatic Encephalopathy: A ReviewJournal of Clinical and Translational Hepatology 2021; 0(000): 000 doi: 10.14218/JCTH.2021.00102
5
Yi-Kuan Tseng, Ken-Ning Hsu. Study design for a three-arm equivalence clinical trial with binomially distributed outcomesJournal of Biopharmaceutical Statistics 2021; 31(6): 736 doi: 10.1080/10543406.2021.1968891
6
Lorenzo Ridola, Angelo Zullo, Cesare Hassan. Rifaximin as treatment for hepatic encephalopathy: Some considerationsSaudi Journal of Gastroenterology 2013; 19(1): 56 doi: 10.4103/1319-3767.105930
7
Halina White. Gastrointestinal Disorders and the Nervous SystemCONTINUUM: Lifelong Learning in Neurology 2020; 26(3): 577 doi: 10.1212/CON.0000000000000871
8
Francesca Romana Ponziani, Viviana Gerardi, Silvia Pecere, Francesca D’Aversa, Loris Lopetuso, Maria Assunta Zocco, Maurizio Pompili, Antonio Gasbarrini. Effect of rifaximin on gut microbiota composition in advanced liver disease and its complicationsWorld Journal of Gastroenterology 2015; 21(43): 12322-12333 doi: 10.3748/wjg.v21.i43.12322
9
Hector Ferral, Elisa Gomez-Reyes, Claus J Fimmel. Post–Transjugular Intrahepatic Portosystemic Shunt Follow-Up and Management in the VIATORR EraTechniques in Vascular and Interventional Radiology 2016; 19(1): 82 doi: 10.1053/j.tvir.2016.01.009
10
Roberto Lorenzetti, Cosimo Prantera. Rationale for the use of rifaximin in inflammatory bowel diseases based on clinical trial resultsClinical Investigation 2013; 3(12): 1187 doi: 10.4155/cli.13.96
11
Daniel Paulson, Mona Shah, Lisa Renee Miller-Matero, Anne Eshelman, Marwan Abouljoud. Cognition Predicts Quality of Life Among Patients With End-Stage Liver DiseasePsychosomatics 2016; 57(5): 514 doi: 10.1016/j.psym.2016.03.006
12
C.E. Coronel-Castillo, J. Contreras-Carmona, A.C. Frati-Munari, M. Uribe, N. Méndez-Sánchez. Eficacia de la rifaximina en los diferentes escenarios clínicos de la encefalopatía hepáticaRevista de Gastroenterología de México 2020; 85(1): 56 doi: 10.1016/j.rgmx.2019.09.001
13
Asmaa N. Mohammad, Mahmoud K. Elsamman, Amr M. Zaghloul, Hameda H. Mohamed, Walaa I. Mohammed. Rifaximin plus cefotaxime versus cefotaxime alone in treatment of spontaneous bacterial peritonitis in patients with cirrhosisThe Egyptian Journal of Internal Medicine 2018; 30(3): 154 doi: 10.4103/ejim.ejim_19_18
14
David Kockerling, Rooshi Nathwani, Roberta Forlano, Pinelopi Manousou, Benjamin H Mullish, Ameet Dhar. Current and future pharmacological therapies for managing cirrhosis and its complicationsWorld Journal of Gastroenterology 2019; 25(8): 888-908 doi: 10.3748/wjg.v25.i8.888
15
Natalia Szóstak, Marek Figlerowicz, Anna Philips. The emerging role of the gut mycobiome in liver diseasesGut Microbes 2023; 15(1) doi: 10.1080/19490976.2023.2211922
16
C.E. Coronel-Castillo, J. Contreras-Carmona, A.C. Frati-Munari, M. Uribe, N. Méndez-Sánchez. Efficacy of rifaximin in the different clinical scenarios of hepatic encephalopathyRevista de Gastroenterología de México (English Edition) 2020; 85(1): 56 doi: 10.1016/j.rgmxen.2019.09.003
17
E. Bouza, L. Alcalá, M. Marín, M. Valerio, E. Reigadas, P. Muñoz, M. González-Del Vecchio, V. de Egea. An outbreak of Clostridium difficile PCR ribotype 027 in Spain: risk factors for recurrence and a novel treatment strategyEuropean Journal of Clinical Microbiology & Infectious Diseases 2017; 36(10): 1777 doi: 10.1007/s10096-017-2991-y
18
Pallab Ray, Shreya Singh, Swati Gupta. Topical Antimicrobial Therapy: Current Status and ChallengesIndian Journal of Medical Microbiology 2019; 37(3): 299 doi: 10.4103/ijmm.IJMM_19_443
19
R. Ennaifer, N. Elleuch, M. Cheikh, H. Romdhane, H. Ben Nejma, N. Bel Hadj. La rifaximine : une nouvelle alternative dans la prévention des infections bactériennes chez le cirrhotique ?Journal Africain d'Hépato-Gastroentérologie 2015; 9(3): 122 doi: 10.1007/s12157-015-0606-8
20
Charlotte Skinner, Alex J. Thompson, Mark R. Thursz, Julian R. Marchesi, Nikhil Vergis. Intestinal permeability and bacterial translocation in patients with liver disease, focusing on alcoholic aetiology: methods of assessment and therapeutic interventionTherapeutic Advances in Gastroenterology 2020; 13: 175628482094261 doi: 10.1177/1756284820942616
21
Angelo Zullo, Lorenzo Ridola, Cesare Hassan. Rifaximin Therapy and Clostridium difficile InfectionJournal of Clinical Gastroenterology 2013; 47(8): 737 doi: 10.1097/MCG.0b013e31828bea4b
22
Amber Ruest. Gastrointestinal Emergencies2019; : 249 doi: 10.1007/978-3-319-98343-1_73
23
Jordi Sanchez-Delgado, Mireia Miquel. Papel de la rifaximina en el tratamiento de la encefalopatía hepáticaGastroenterología y Hepatología 2016; 39(4): 282 doi: 10.1016/j.gastrohep.2015.08.003
24
Yuval Ishay, Yotam Kolben, Asa Kessler, Yaron Ilan. Role of circadian rhythm and autonomic nervous system in liver function: a hypothetical basis for improving the management of hepatic encephalopathyAmerican Journal of Physiology-Gastrointestinal and Liver Physiology 2021; 321(4): G400 doi: 10.1152/ajpgi.00186.2021
25
Khadija A. M. Glal, Sherief M. Abd‐Elsalam, Tarek M. Mostafa. Nitazoxanide versus rifaximin in preventing the recurrence of hepatic encephalopathy: A randomized double‐blind controlled trialJournal of Hepato-Biliary-Pancreatic Sciences 2021; 28(10): 812 doi: 10.1002/jhbp.947
26
Axel Holstege. Hepatische Enzephalopathie Teil 2: TherapieGastroenterologie up2date 2023; 19(04): 357 doi: 10.1055/a-2039-9694
27
Jordi Sanchez-Delgado, Mireia Miquel. Role of rifaximin in the treatment of hepatic encephalopathyGastroenterología y Hepatología (English Edition) 2016; 39(4): 282 doi: 10.1016/j.gastre.2016.03.006
28
T. E. Polunina. Risk stratification in alcoholic cirrhosis of the liver: a case studyMeditsinskiy sovet = Medical Council 2023; (8): 126 doi: 10.21518/ms2023-129
29
Motoh Iwasa, Yoshiyuki Takei. Pathophysiology and management of hepatic encephalopathy 2014 update: Ammonia toxicity and hyponatremiaHepatology Research 2015; 45(12): 1155 doi: 10.1111/hepr.12495